Search Ontology:
ChEBI
BMS-214662
- Term ID
- CHEBI:167655
- Synonyms
-
- (3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-(thiophen-2-ylsulfonyl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-7-carbonitrile
- (3R)-3-benzyl-1-(1H-imidazol-5-ylmethyl)-4-thiophen-2-ylsulfonyl-3,5-dihydro-2H-1,4-benzodiazepine-7-carbonitrile
- (R)-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine-7-carbonitrile
- (R)-7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine
- BMS 214662
- BMS214662
- Definition
- A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.
- References
-
- cas:195987-41-8
- chemspider:395310
- drugbank:DB12234
- pdb-ccd:BMV
- pubmed:11020273
- pubmed:11606387
- pubmed:12789624
- pubmed:15073096
- pubmed:15102665
- pubmed:15170324
- pubmed:15356656
- pubmed:15710949
- pubmed:15728224
- pubmed:15738311
- pubmed:15756013
- pubmed:15930351
- pubmed:16362299
- pubmed:17510207
- pubmed:17956348
- pubmed:18156496
- pubmed:19738029
- pubmed:19883257
- pubmed:21483442
- pubmed:23184491
- pubmed:27688185
- Ontology
- ChEBI ( EBI )
Phenotype
Phenotype resulting from BMS-214662
Phenotype where environments contain BMS-214662
Phenotype modified by environments containing BMS-214662
Phenotype affecting BMS-214662
Human Disease Model